Abstract 1742P
Background
The US Surveillance, Epidemiology and End Result (SEER) data indicate an increasing incidence of early-onset cancer across the GI tract. A female predominance has been shown for early-onset pancreatic cancer (EOPC) in the US. Due to environmental factors which may underlie the pathogenesis of early-onset cancer, incidence across the globe may differ. However, data regarding the incidence of gastrointestinal cancers in young patients in Europe is scarce. Therefore, we aimed to investigate patterns of GI cancers in young patients across various European countries.
Methods
National cancer registries of seven European countries - Germany, Netherlands, Spain, Slovenia, Norway, Czech Republic and Israel - were approached for absolute number of cancer incidences per age group (15-50 years in 5-year intervals) and the size of the population for each age group yearly from 2008-2018. Data was analyzed to calculate year-by-year the Average Annual Incidence Rate Change (AARC) and Average Annual Percent Change (AAPC).
Results
We observed heterogeneous patterns in different GI cancers across countries. An increase was noted in oesophageal cancer in females in the Czech Republic and Germany (AAPC 11.65% and 1.11% respectively) and slightly in males in the Netherlands (AAPC 0.88%) and Slovenia (AAPC 0.40%). Gastric cancer increased in females in Norway (AAPC 15.00%) and Slovenia (AAPC 11.90%). An increase in incidence of EOPC in men and women was noted in Germany, Norway and Netherlands and in females in Israel and Slovenia (AAPC 6.0%, 4.30% respectively). Early-Onset Colorectal cancer (EOCRC) is on the rise in men and women in Israel, Netherlands and Norway, while increasing only in males in the Czech Republic (AAPC 1.50%) and only in females in Slovenia (AAPC 5.40%). In Spain, only EOCRC showed an increased incidence.
Conclusions
The incidence of early-onset cancer along the GI tract displays differential patterns across countries, which differs from the trends observed in SEER data. In some GI cancers the incidence is stable between 2008-2018 and some are increasing mainly in women. Due to the environmental role in the pathogenesis of early-onset GI cancer, future studies should unravel potential etiologies especially with regard to gender-related factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2375P - Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
Presenter: Zhou Tong
Session: Poster session 23
2376P - Pembrolizumab monotherapy following tri-modality treatment for selected patients with muscle-invasive bladder cancer
Presenter: Shang Bin Qin
Session: Poster session 23
2378P - Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment
Presenter: Vadim Koshkin
Session: Poster session 23
2379P - AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Presenter: Philippe Barthélémy
Session: Poster session 23